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ABSTRACT 
Coibamide A is a highly potent antiproliferative cyclic depsipeptide, which was originally isolated 
from a Panamanian marine cyanobacterium. In this study, the synthesis of coibamide A has been 
investigated using Fmoc-based solid-phase peptide synthesis followed by the cleavage of the resulting 
linear peptide from the resin and its subsequent macrolactonization. The peptide sequence of the linear 
coibamide A precursor was constructed on a solid-support following the optimization of the coupling 
conditions, where numerous coupling agents were evaluated. The macrocyclization of the resulting 
linear peptide provided the [D-MeAla11]-epimer of coibamide A, which exhibited nanomolar cytotoxic 
activity towards a number of human cancer cell lines. 
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Abbreviations: Hva = -Hydroxyisovaleric acid; HATU = O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetra-
methyluronium hexafluorophosphate; BTC = Bis(trichloromethyl) carbonate; DIC = 1,3-diisopropyl- 
carbodiimide; HOBt = 1-hydroxybenzotriazole; HOAt = 1-hydroxy-7-azabenzotriazole; TFA = 
trifluoroacetic acid; MSNT = 1-(mesitylene-2-sulfonyl)-3-nitro-1,2,4-triazole; NMI = N-methyl- 
imidazole; DCM = dichloromethane. 
 Coibamide A (1) is a cyclic depsipeptide, which was originally isolated from a Panamanian 
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Coibamide A (1) is a cyclic depsipeptide, which was originally isolated from a Panamanian marine 
cyanobacterium (Figure 1).1 This compound has been reported to exhibit potent antiproliferative activity 
against a number of human cell lines, where it operates according to a unique mechanism of action. For 
this reason, there has been considerable interest in the use of coibamide A as a potential lead in cancer 
drug discovery. The recent results also revealed that coibamide A induces macroautophagy and can 
trigger apoptosis and non-apoptotic forms of cell death in human cancer cells.2 The production and 
isolation of coibamide A via the cultivation of coibamide A-producing cyanobacterium is a laborious 
process, and the development of new methods for the chemical synthesis of coibamide A and its 
derivatives is therefore highly desired to allow for further pharmaceutical research and development.1 
The proposed structure of coibamide A was recently synthesized by He et al.,3 but the analytical and 
biological activity data for the synthetic sample were inconsistent with those reported for natural 
coibamide A. 
Coibamide A has eight N-methylamino acids and two ester bonds. The coupling of an amino acid 
onto the N-methylamino terminus of a peptidyl resin proceeds slowly because of steric hindrance, and 
the synthesis of N-methyl-rich peptides can be made difficult by the sluggish nature of this reaction.4 
The synthesis of N-methyl-rich peptides on a solid-support therefore requires the optimization of the 
reagent used for each coupling step, as exemplified by the syntheses of [MeLeu1]-cyclosporin A,5 the 
potent nematicide omphalotin A,6 the antitumor agent IB-012127 and the immunosuppressive antifungal 
compound petriellin A.8 The coupling conditions developed for the synthesis of [MeLeu1]-cyclosporin 
A5 involved the use a highly reactive DIC/1-hydroxy-7-azabenzotriazole (HOAt) system9 and 
O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU),10 which led to 
significant improvements in the yields of the coupling products. Bis(trichloromethyl)carbonate (BTC) 
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has also been used to improve the coupling efficiency of amidation reactions by converting Fmoc-amino 
acids into highly reactive and sterically unhindered acid chlorides in situ.6 
It was envisaged in the current study that coibamide A could be synthesized via the Fmoc-based 
solid-phase peptide synthesis (SPPS) of a linear peptidyl resin, followed by the cleavage of the resulting 
linear peptide from the resin and a subsequent macrocyclization reaction between its MeThr5 -hydroxy 
group and its C-terminal carboxylic acid moiety (Scheme 1). A series of different coupling protocols 
were investigated in the current study, including the use of DIC/HOAt, HATU and BTC systems to 
optimize the coupling conditions required for all seven of the N-methylamino acid-termini on the 
solid-support. The progress of each coupling reaction was monitored by HPLC analysis following the 
cleavage of the peptide product from the peptidyl resin with a 5:95 (v/v) mixture of TFA/DCM. 
Tyr(Me)10 and Ala8 were efficiently coupled to N-methylamino acids using a HATU/(i-Pr)2NEt 
system. In contrast, MeLeu9 and MeIle7 were successfully coupled onto unmethylated amino acids using 
the standard protocol for Fmoc-based SPPS (i.e., DIC/HOBt). The coupling of MeSer(Me)6 onto the 
N-methylamino group of MeIle7 in the presence of HATU/(i-Pr)2NEt led to the partial epimerization of 
the product (dr = 72:28), which was attributed to slow reaction of the two coupling partners under the 
basic conditions. When the same coupling reaction was conducted with DIC/HOAt, which produces an 
HOAt ester as the active species without the addition of base, the reaction did not proceed to completion, 
although no epimerization was observed. In contrast, the coupling of Fmoc-Ser(Me)-OH proceeded 
smoothly to completion using the same DIC/HOAt reagents. Subsequent deprotection of the Fmoc group 
followed by an on-resin N-methylation protocol using an o-nitrobenzenesulfonyl (Ns)-strategy (Scheme 
2)11 provided the desired hexapeptide containing MeSer(Me)6 in sufficient purity. Overall, this 
N-methylation protocol involved the nosylation of the Ser(Me) -amino group, N-methylation of the 
resulting nosylated amine using a Mitsunobu reaction and the subsequent deprotection of the Ns-group. 
5 
The coupling of Fmoc-Thr(Trt)-OH was also followed by an on-resin N-methylation process using the 
Ns-strategy described above to give the MeThr(Trt)5 residue. 
As was the case for MeSer(Me)6, the HATU-mediated coupling of MeLeu4 did not proceed to 
completion (61% conversion). The failure of this reaction to reach completion was most likely due to 
steric hindrance of the N-methylamino group and the protected bulky side chain of MeThr(Trt)5. Among 
the various coupling conditions investigated, BTC was found to be the only coupling agent capable of 
driving the MeLeu4 coupling to completion to obtain the desired octapeptide in good purity (83% purity). 
The second MeSer(Me)3 residue was also incorporated into the linear peptide by the BTC-mediated 
coupling of Fmoc-MeSer(Me)-OH, which was synthesized according to the Freidinger method.12 Finally, 
to allow for the incorporation of the N-terminal esterified dimer (Me2Val1-Hva2) into the linear peptide 
resin, the resulting nonapeptide was conjugated to ester 3 using DIC/HOAt; ester 3 was synthesized in 
advance of this particular step using solution phase chemistry. The resulting peptide was then 
N,N-dimethylated under reductive amination conditions with formalin and NaBH(OAc)3 to afford the 
desired linear undecapeptidyl resin 2 in 52% purity. 
The final deprotection and cleavage of peptidyl resin 2 was achieved by the treatment of the 
resin-bound peptide with a 5:95 (v/v) mixture of TFA/DCM, which led to the formation of two products 
with identical molecular weights (Figure 2). The treatment of the minor product with Et3N provided only 
the major product, while the major product underwent partial conversion to the minor product by 
treatment with TFA/DCM (5:95) (accompanied by the unchanged major product). These suggested that 
the major product was the desired linear peptide 4, and that the minor product was the O-acyl peptide 5, 
which was most likely formed by the rearrangement of the N-terminal tetrapeptide from the MeThr5 
-amino group to the side-chain hydroxyl group. The desired product 4 could be recovered by the 
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treatment of the mixture of 4 and 5 with Et3N followed by purification by reversed-phase HPLC. The 
overall isolated yield of 4 from resin 1 was 29%. 
With the linear precursor 4 in hand, we proceeded to investigate the macrolactonization using 
LC-MS analysis to monitor the reaction progress. Although various macrolactonization conditions have 
been reported in the literature,13-17 the application of these conditions to peptide 4 failed to provide any 
of the desired cyclic depsipeptide. Pleasingly, however, the use of MSNT7/(i-Pr)2NEt provided access to 
the desired cyclization product, albeit in a low yield of 3.8%. 
The cyclic product was characterized by ESI-MS, MALDI-TOF-MS and ESI-TOF-MS/MS 
analyses (Figure 3). The expected molecular ions were detected by ESI-MS ([M+2H]2+, [M+H]+ and 
[M+Na]+) and MALDI-TOF-MS ([M+H]+ and [M+Na]+). Analysis of the cyclic peptide by 
ESI-TOF-MS/MS revealed that its fragmentation pattern was identical to that of the natural product, 
except that an MS/MS fragmentation peak with an m/z value of 880 was not observed for the synthetic 
material. The 13C NMR spectrum of the synthetic product was almost identical to that of the natural 
product (see supplementary data). Although the 1H NMR spectrum of the synthetic product was similar 
to that of natural coibamide A (Figure S1), significant differences were observed in the regions spanning 
 1.4–1.7 and 4.5–6.2 ppm (Figure 4). In particular, there were considerable differences between the 1H 
signals attributed to MeLeu4--CH2, MeSer(Me)3--CH and Hva2--CH. A comparison of these two 
compounds by HPLC analysis revealed that the synthetic product eluted slightly ahead of the natural 
product, which indicated that the synthetic product could be a diastereomer of the natural product. It is 
entirely possible that the MeAla11 residue may have been epimerized during the macrolactonization step 
and that only the epimerized precursor underwent the cyclization reaction to provide the corresponding 
cyclic product, which had an identical molecular weight. The configurations of the hydroxy and amino 
acids moieties of the synthetic product were therefore investigated using Marfey’s analysis (by LC-MS) 
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and chiral GC-MS using similar methods to those published previously for the analysis of natural 
coibamide A.1 Based on the results of this analysis (see supplementary data), the MeAla residue of the 
synthetic precursor was assigned as D configuration, which confirmed our suspicions that the extended 
reaction time required for the macrolactonization process had resulted in the racemization and selective 
cyclization of the linear [D-MeAla11]-undecapeptide. 
Initial biological testing of this [D-MeAla11]-epimer of coibamide A revealed that it was potently 
cytotoxic against A549 (non-small cell lung cancer), HCT116 (colon cancer), MCF-7 (breast cancer) 
and B16 (murine melanoma) cells at nanomolar concentrations (Table 1). The cytotoxicity of the 
[D-MeAla11]-epimer of coibamide A was also directly compared with that of natural coibamide A 
against a panel of four additional human cancer cell lines including H292 (lung carcinoma), 
MDA-MB-231 (breast cancer), PC-3 (prostate cancer) and SF-295 (glioblastoma) cells. The 
[D-MeAla11]-epimer of coibamide A showed potent cytotoxic activity towards all four of these cell lines, 
although the potency exhibited by this material was 3.7- to 8.3-fold less than that of natural coibamide A 
(Table 2). 
In conclusion, we have investigated the synthesis of coibamide A using Fmoc-SPPS followed by 
the macrolactonization of the resulting linear peptide. The coupling conditions used for the solid-phase 
synthesis were optimized to obtain the linear precursor in high yield. During the macrocyclization 
process, only the [D-MeAla11]-epimer was obtained, most likely because of the epimerization of the 
MeAla11 residue during the slow ester bond formation. The [D-MeAla11]-epimer of coibamide A was 
found to be slightly less potent than the natural coibamide A, but still exhibited nanomolar cytotoxicity 
towards a number of different cancer cell lines, and is the first in a series of coibamide A epimers that 
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Table 1. Cytotoxicities of [D-MeAla11]-coibamide A against human non-small cell lung (A549), colon 
(HCT116), breast (MCF-7) and murine melanoma (B16) cancer cell lines.a 





aConcentration-response relationships were analyzed using Graphpad Prism Software (Graphpad 




Table 2. Comparative cytotoxicities for natural coibamide A and the [D-MeAla11]-epimer of coibamide 
A against human lung carcinoma (H292), breast (MDA-MB-231), prostate (PC-3) and glioblastoma 
(SF-295) cancer cell lines.a 
cell line IC50 (nM)  




H292 124 610  
MDA-MB-231 66 545 
PC-3 80  424  
SF-295 219 816  
aConcentration-response relationships were analyzed using Graphpad Prism Software, and IC50 values 
were derived using nonlinear regression analysis fit to a logistic equation. 
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Figure 2. Possible N- to O-acyl shift at the MeThr5 residue following the treatment of linear 
undecapeptide 4 with a 5:95 (v/v) mixture of TFA/DCM. 
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Figure 3. Mass spectrometric analysis of synthetic [D-MeAla11]-coibamide A. (a) ESI-MS spectrum, (b) 
MALDI-TOF-MS spectrum, (c) ESI-TOF-MS/MS spectrum, and (d) the reported MS/MS fragmentation 
pattern of natural coibamide A. 
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Figure 4. Comparison of A) the alkyl- and upper N-methyl and B) the -proton and aromatic regions of 
the 1H NMR spectra for synthetic [D-MeAla11]-coibamide A (upper) and natural coibamide A (lower). 
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Scheme 1. Overview of the synthetic strategy used for the construction of coibamide A. 
 
 
Scheme 2. Preparation of N-methylamino acids [i.e., MeSer(Me)6 and MeThr(Trt)5] using the 
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